KDR and small cell lung carcinoma: In a phase II clinical trial lead by Horn L. et al., for example, the VEGFR inhibitor bevacizumab was added to etoposide and cisplatin and used as a first-line therapy for people with advanced stage small cell lung cancer (SCLC), and this resulted in an increase in the survival rate compared to historical controls who received this chemotherapy regimen without bevacizumab [66].